Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HSA-rhGH versus recombinant human somatropin in prepubertal children with growth hormone deficiency
ChiCTR2400086151Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of albusomatropin and somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Annualized height velocity at week 52. Started Jun 2024; status: recruiting.
02
Drugs
albusomatropinsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on ChiCTR2400086151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086151.